She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

NEW YORK, NY / ACCESS Newswire / February 15, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...

Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...